文献速递组学、生物样本库与精准医学基础与转化研究

酒精相关性肝病的无创蛋白质组学生物标志物

Noninvasive proteomic biomarkers for alcohol-related liver disease.
PubMed 文献 · Nat Med · 2022-06-02

研究对596人(137名对照、459名酒精相关性肝病患者,其中360人有活检组织学评估)采用肝-血浆配对蛋白质组学方法,用质谱分析全部血浆样本和79份肝活检。机器学习模型识别的蛋白质组标志物组合检测显著纤维化(ROC-AUC 0.92,准确率0.82)和轻度炎症(ROC-AUC 0.87,准确率0.79)优于现有临床检测(DeLong检验P < 0.05),预测未来肝脏相关事件和全因死亡的Harrell's C-index分别为0.90和0.79,独立验证队列重现了诊断模型性能。

要点

  • 血浆蛋白质组标志物组合检测显著纤维化ROC-AUC 0.92、准确率0.82,优于现有临床检测。
  • 该组合检测轻度炎症ROC-AUC 0.87、准确率0.79,优于现有临床检测。
  • 标志物组合预测未来肝脏相关事件Harrell's C-index 0.90、全因死亡0.79。

核心结论

  • 血浆蛋白质组标志物组合可较准确检测酒精相关性肝病的显著纤维化和轻度炎症,并预测未来肝脏相关事件和全因死亡。

研究设计与样本

  • 研究纳入596人(137名对照和459名酒精相关性肝病患者),其中360人接受活检组织学评估。
  • 采用肝-血浆配对蛋白质组学方法,用质谱分析全部血浆样本和79份肝活检,测量时间仅3周。

主要发现

  • 血浆和肝活检组织中代谢功能下调,纤维化相关信号和免疫反应上调。
  • 机器学习模型识别的蛋白质组标志物组合检测显著纤维化ROC-AUC 0.92、准确率0.82,检测轻度炎症ROC-AUC 0.87、准确率0.79,均优于现有临床检测(DeLong检验P < 0.05)。
  • 标志物组合预测未来肝脏相关事件Harrell's C-index 0.90,预测全因死亡Harrell's C-index 0.79。
  • 独立验证队列重现了诊断模型性能。

关键数值与推荐

  • 显著纤维化检测:ROC-AUC 0.92,准确率0.82。
  • 轻度炎症检测:ROC-AUC 0.87,准确率0.79。
  • 未来肝脏相关事件预测:Harrell's C-index 0.90。
  • 全因死亡预测:Harrell's C-index 0.79。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alcohol-related liver disease (ALD) is a major cause of liver-related death worldwide, yet understanding of the three key pathological features of the disease-fibrosis, inflammation and steatosis-remains incomplete. Here, we present a paired liver-plasma proteomics approach to infer molecular pathophysiology and to explore the diagnostic and prognostic capability of plasma proteomics in 596 individuals (137 controls and 459 individuals with ALD), 360 of whom had biopsy-based histological assessment. We analyzed all plasma samples and 79 liver biopsies using a mass spectrometry (MS)-based proteomics workflow with short gradient times and an enhanced, data-independent acquisition scheme in only 3 weeks of measurement time. In plasma and liver biopsy tissues, metabolic functions were downregulated whereas fibrosis-associated signaling and immune responses were upregulated. Machine learning models identified proteomics biomarker panels that detected significant fibrosis (receiver operating characteristic-area under the curve (ROC-AUC), 0.92, accuracy, 0.82) and mild inflammation (ROC-AUC, 0.87, accuracy, 0.79) more accurately than existing clinical assays (DeLong's test, P < 0.05). These biomarker panels were found to be accurate in prediction of future liver-related events and all-cause mortality, with a Harrell's C-index of 0.90 and 0.79, respectively. An independent validation cohort reproduced the diagnostic model performance, laying the foundation for routine MS-based liver disease testing.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Niu L, Thiele M, Geyer PE, et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat Med. 2022. PMID: 35654907. doi:10.1038/s41591-022-01850-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。